| 1 | the risk of pml | | | | | | | 3 | 0.17% |
| 2 | increases the risk of | | | | | | | 3 | 0.17% |
| 3 | available only through a | | | | | | | 2 | 0.11% |
| 4 | contraindicated in patients who | | | | | | | 2 | 0.11% |
| 5 | exposure to tysabri a | | | | | | | 2 | 0.11% |
| 6 | utero exposure to tysabri | | | | | | | 2 | 0.11% |
| 7 | in utero exposure to | | | | | | | 2 | 0.11% |
| 8 | suggestive of pml for | | | | | | | 2 | 0.11% |
| 9 | in patients who have | | | | | | | 2 | 0.11% |
| 10 | studies ms1 and ms2 | | | | | | | 2 | 0.11% |
| 11 | in studies ms1 and | | | | | | | 2 | 0.11% |
| 12 | tysabri is contraindicated in | | | | | | | 2 | 0.11% |
| 13 | is contraindicated in patients | | | | | | | 2 | 0.11% |
| 14 | patients who did not | | | | | | | 2 | 0.11% |
| 15 | the risk of developing | | | | | | | 2 | 0.11% |
| 16 | viral infection of the | | | | | | | 2 | 0.11% |
| 17 | in the postmarketing setting | | | | | | | 2 | 0.11% |
| 18 | for any new sign | | | | | | | 2 | 0.11% |
| 19 | for the development of | | | | | | | 2 | 0.11% |
| 20 | the development of pml | | | | | | | 2 | 0.11% |
| 21 | tysabri should be discontinued | | | | | | | 2 | 0.11% |
| 22 | signs of liver injury | | | | | | | 2 | 0.11% |
| 23 | with in utero exposure | | | | | | | 2 | 0.11% |
| 24 | is available only through | | | | | | | 2 | 0.11% |
| 25 | reported in patients treated | | | | | | | 2 | 0.11% |
| 26 | of the risk of | | | | | | | 2 | 0.11% |
| 27 | patients with pml who | | | | | | | 2 | 0.11% |
| 28 | tysabri increases the risk | | | | | | | 2 | 0.11% |
| 29 | risk of pml tysabri | | | | | | | 2 | 0.11% |
| 30 | been reported in patients | | | | | | | 2 | 0.11% |
| 31 | of pml tysabri is | | | | | | | 2 | 0.11% |
| 32 | in patients treated with | | | | | | | 2 | 0.11% |
| 33 | patients treated with tysabri | | | | | | | 2 | 0.11% |
| 34 | pml tysabri is available | | | | | | | 2 | 0.11% |
| 35 | tysabri is available only | | | | | | | 2 | 0.11% |
| 36 | in multiple sclerosis patients | | | | | | | 1 | 0.06% |
| 37 | fatal cases have been | | | | | | | 1 | 0.06% |
| 38 | cases have been reported | | | | | | | 1 | 0.06% |
| 39 | itp have been reported | | | | | | | 1 | 0.06% |
| 40 | the postmarketing setting in | | | | | | | 1 | 0.06% |